Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL30P4 (ribosomal protein L30 pseudogene 4) is classified as a processed pseudogene in the human genome, closely related in sequence to the functional RPL30 gene but with mutations (such as premature stop codons or truncations) that prevent it from encoding a functional protein. Pseudogenes like RPL30P4 are typically considered nonfunctional remnants of evolutionary events. There is no evidence for a direct biological or pathophysiological role, nor any association with drug response or disease, and these sequences are not considered therapeutic targets or biomarkers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L30 pseudogene 4 (RPL30P4).